GrippeCanadaV4, Main, Corpus, bibRecord, 000084

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Identifieur interne : 000084 ( Main/Corpus ); précédent : 000083; suivant : 000085

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Auteurs : Danuta M. Skowronski ; Catharine Chambers ; Suzana Sabaiduc ; Gaston De Serres ; Anne-Luise Winter ; James A. Dickinson ; Jonathan B. Gubbay ; Steven J. Drews ; Christine Martineau ; Hugues Charest ; Mel Krajden ; Nathalie Bastien ; Yan Li

Source :

The Journal of infectious diseases [ 1537-6613 ] ; 2017.

RBID : pubmed:29029166

English descriptors

KwdEn :
- Adult (MeSH), Age Factors (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antigenic Variation (MeSH), Antigens, Viral (immunology), Canada (epidemiology), Child (MeSH), Child, Preschool (MeSH), Cluster Analysis (MeSH), Female (MeSH), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Immunization (methods), Immunogenicity, Vaccine (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (classification), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza B virus (classification), Influenza B virus (genetics), Influenza B virus (immunology), Influenza B virus (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Phylogeny (MeSH), Sequence Analysis, DNA (MeSH), Sequence Homology (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Antigens, Viral, Influenza Vaccines.
- geographic , epidemiology : Canada.
- classification : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza B virus.
- methods : Immunization.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adult, Age Factors, Aged, Aged, 80 and over, Antigenic Variation, Child, Child, Preschool, Cluster Analysis, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Infant, Male, Middle Aged, Phylogeny, Sequence Analysis, DNA, Sequence Homology, Treatment Outcome, Young Adult.

Abstract

Background

Vaccine effectiveness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Sentinel Practitioner Surveillance Network (SPSN). This season was characterized by a delayed 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) epidemic and concurrent influenza B(Victoria) virus activity. Potential influences on VE beyond antigenic match are explored, including viral genomic variation, birth cohort effects, prior vaccination, and epidemic period.

Methods

VE was estimated by a test-negative design comparing the adjusted odds ratio for influenza test positivity among vaccinated compared to unvaccinated participants. Vaccine-virus relatedness was assessed by gene sequencing and hemagglutination inhibition assay.

Results

Analyses included 596 influenza A(H1N1)pdm09 and 305 B(Victoria) cases and 926 test-negative controls. A(H1N1)pdm09 viruses were considered antigenically related to vaccine (unchanged since 2009), despite phylogenetic clustering within emerging clade 6B.1. The adjusted VE against A(H1N1)pdm09 was 43% (95% confidence interval [CI], 25%-57%). Compared to other age groups, VE against A(H1N1)pdm09 was lower for adults born during 1957-1976 (25%; 95% CI, -16%-51%). The VE against A(H1N1)pdm09 was also lower for participants consecutively vaccinated during both the current and prior seasons (41%; 95% CI, 18%-57%) than for those vaccinated during the current season only (75%; 95% CI, 45%-88%), and the VE among participants presenting in March-April 2016 (19%; 95% CI, -15%-44%) was lower than that among those presenting during January-February 2016 (62%; 95% CI, 44%-74%). The adjusted VE for B(Victoria) viruses was 54% (95% CI, 32%-68%), despite lineage-level mismatch to B(Yamagata) vaccine. The further variation in VE as observed for A(H1N1)pdm09 was not observed for B(Victoria).

Conclusions

Influenza VE findings may require consideration of other agent-host and immuno-epidemiologic influences on vaccine performance beyond antigenic match, including viral genomic variation, repeat vaccination, birth (immunological) cohort effects, and potential within-season waning of vaccine protection.

DOI: 10.1093/infdis/jix526
PubMed: 29029166
PubMed Central: PMC5853508

Links to Exploration step

pubmed:29029166

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chambers, Catharine" sort="Chambers, Catharine" uniqKey="Chambers C" first="Catharine" last="Chambers">Catharine Chambers</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Laval University, Québec.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire de Québec, Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name>
<affiliation><nlm:affiliation>University of Calgary, Calgary.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of Toronto, Toronto.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation><nlm:affiliation>Alberta Provincial Laboratory, Edmonton.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of Alberta, Edmonton.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martineau, Christine" sort="Martineau, Christine" uniqKey="Martineau C" first="Christine" last="Martineau">Christine Martineau</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29029166</idno>
<idno type="pmid">29029166</idno>
<idno type="doi">10.1093/infdis/jix526</idno>
<idno type="pmc">PMC5853508</idno>
<idno type="wicri:Area/Main/Corpus">000084</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000084</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chambers, Catharine" sort="Chambers, Catharine" uniqKey="Chambers C" first="Catharine" last="Chambers">Catharine Chambers</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Laval University, Québec.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire de Québec, Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name>
<affiliation><nlm:affiliation>University of Calgary, Calgary.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of Toronto, Toronto.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation><nlm:affiliation>Alberta Provincial Laboratory, Edmonton.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of Alberta, Edmonton.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martineau, Christine" sort="Martineau, Christine" uniqKey="Martineau C" first="Christine" last="Martineau">Christine Martineau</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of infectious diseases</title>
<idno type="eISSN">1537-6613</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Age Factors (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antigenic Variation (MeSH)</term>
<term>Antigens, Viral (immunology)</term>
<term>Canada (epidemiology)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Cluster Analysis (MeSH)</term>
<term>Female (MeSH)</term>
<term>Hemagglutination Inhibition Tests (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunization (methods)</term>
<term>Immunogenicity, Vaccine (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (classification)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza B virus (classification)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza B virus (isolation & purification)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Phylogeny (MeSH)</term>
<term>Sequence Analysis, DNA (MeSH)</term>
<term>Sequence Homology (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antigenic Variation</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cluster Analysis</term>
<term>Female</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Immunogenicity, Vaccine</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phylogeny</term>
<term>Sequence Analysis, DNA</term>
<term>Sequence Homology</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Background</b>
</p>
<p>Vaccine effectiveness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Sentinel Practitioner Surveillance Network (SPSN). This season was characterized by a delayed 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) epidemic and concurrent influenza B(Victoria) virus activity. Potential influences on VE beyond antigenic match are explored, including viral genomic variation, birth cohort effects, prior vaccination, and epidemic period.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Methods</b>
</p>
<p>VE was estimated by a test-negative design comparing the adjusted odds ratio for influenza test positivity among vaccinated compared to unvaccinated participants. Vaccine-virus relatedness was assessed by gene sequencing and hemagglutination inhibition assay.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>Analyses included 596 influenza A(H1N1)pdm09 and 305 B(Victoria) cases and 926 test-negative controls. A(H1N1)pdm09 viruses were considered antigenically related to vaccine (unchanged since 2009), despite phylogenetic clustering within emerging clade 6B.1. The adjusted VE against A(H1N1)pdm09 was 43% (95% confidence interval [CI], 25%-57%). Compared to other age groups, VE against A(H1N1)pdm09 was lower for adults born during 1957-1976 (25%; 95% CI, -16%-51%). The VE against A(H1N1)pdm09 was also lower for participants consecutively vaccinated during both the current and prior seasons (41%; 95% CI, 18%-57%) than for those vaccinated during the current season only (75%; 95% CI, 45%-88%), and the VE among participants presenting in March-April 2016 (19%; 95% CI, -15%-44%) was lower than that among those presenting during January-February 2016 (62%; 95% CI, 44%-74%). The adjusted VE for B(Victoria) viruses was 54% (95% CI, 32%-68%), despite lineage-level mismatch to B(Yamagata) vaccine. The further variation in VE as observed for A(H1N1)pdm09 was not observed for B(Victoria).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusions</b>
</p>
<p>Influenza VE findings may require consideration of other agent-host and immuno-epidemiologic influences on vaccine performance beyond antigenic match, including viral genomic variation, repeat vaccination, birth (immunological) cohort effects, and potential within-season waning of vaccine protection.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29029166</PMID>
<DateCompleted><Year>2019</Year>
<Month>03</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>216</Volume>
<Issue>12</Issue>
<PubDate><Year>2017</Year>
<Month>12</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of infectious diseases</Title>
<ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.</ArticleTitle>
<Pagination><MedlinePgn>1487-1500</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jix526</ELocationID>
<Abstract><AbstractText Label="Background">Vaccine effectiveness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Sentinel Practitioner Surveillance Network (SPSN). This season was characterized by a delayed 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) epidemic and concurrent influenza B(Victoria) virus activity. Potential influences on VE beyond antigenic match are explored, including viral genomic variation, birth cohort effects, prior vaccination, and epidemic period.</AbstractText>
<AbstractText Label="Methods">VE was estimated by a test-negative design comparing the adjusted odds ratio for influenza test positivity among vaccinated compared to unvaccinated participants. Vaccine-virus relatedness was assessed by gene sequencing and hemagglutination inhibition assay.</AbstractText>
<AbstractText Label="Results">Analyses included 596 influenza A(H1N1)pdm09 and 305 B(Victoria) cases and 926 test-negative controls. A(H1N1)pdm09 viruses were considered antigenically related to vaccine (unchanged since 2009), despite phylogenetic clustering within emerging clade 6B.1. The adjusted VE against A(H1N1)pdm09 was 43% (95% confidence interval [CI], 25%-57%). Compared to other age groups, VE against A(H1N1)pdm09 was lower for adults born during 1957-1976 (25%; 95% CI, -16%-51%). The VE against A(H1N1)pdm09 was also lower for participants consecutively vaccinated during both the current and prior seasons (41%; 95% CI, 18%-57%) than for those vaccinated during the current season only (75%; 95% CI, 45%-88%), and the VE among participants presenting in March-April 2016 (19%; 95% CI, -15%-44%) was lower than that among those presenting during January-February 2016 (62%; 95% CI, 44%-74%). The adjusted VE for B(Victoria) viruses was 54% (95% CI, 32%-68%), despite lineage-level mismatch to B(Yamagata) vaccine. The further variation in VE as observed for A(H1N1)pdm09 was not observed for B(Victoria).</AbstractText>
<AbstractText Label="Conclusions">Influenza VE findings may require consideration of other agent-host and immuno-epidemiologic influences on vaccine performance beyond antigenic match, including viral genomic variation, repeat vaccination, birth (immunological) cohort effects, and potential within-season waning of vaccine protection.</AbstractText>
<CopyrightInformation>© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName>
<ForeName>Danuta M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of British Columbia, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chambers</LastName>
<ForeName>Catharine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sabaiduc</LastName>
<ForeName>Suzana</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Serres</LastName>
<ForeName>Gaston</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Laval University, Québec.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Québec, Québec.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winter</LastName>
<ForeName>Anne-Luise</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dickinson</LastName>
<ForeName>James A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>University of Calgary, Calgary.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gubbay</LastName>
<ForeName>Jonathan B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Toronto, Toronto.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drews</LastName>
<ForeName>Steven J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>Alberta Provincial Laboratory, Edmonton.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Alberta, Edmonton.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martineau</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Charest</LastName>
<ForeName>Hugues</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Krajden</LastName>
<ForeName>Mel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of British Columbia, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bastien</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Infect Dis</MedlineTA>
<NlmUniqueID>0413675</NlmUniqueID>
<ISSNLinking>0022-1899</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Infect Dis. 2017 Dec 19;216(12):1477-1480</RefSource>
<PMID Version="1">29029175</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000940" MajorTopicYN="N">Antigenic Variation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017385" MajorTopicYN="N">Sequence Homology</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Influenza</Keyword>
<Keyword MajorTopicYN="Y">birth cohort effects</Keyword>
<Keyword MajorTopicYN="Y">hemagglutination inhibition</Keyword>
<Keyword MajorTopicYN="Y">influenza A subtype</Keyword>
<Keyword MajorTopicYN="Y">influenza B lineage</Keyword>
<Keyword MajorTopicYN="Y">influenza vaccine</Keyword>
<Keyword MajorTopicYN="Y">original antigenic sin</Keyword>
<Keyword MajorTopicYN="Y">repeat vaccination</Keyword>
<Keyword MajorTopicYN="Y">sequencing</Keyword>
<Keyword MajorTopicYN="Y">vaccine effectiveness</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>3</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29029166</ArticleId>
<ArticleId IdType="pii">4356858</ArticleId>
<ArticleId IdType="doi">10.1093/infdis/jix526</ArticleId>
<ArticleId IdType="pmc">PMC5853508</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Curr Opin Virol. 2017 Feb;22:105-111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28088686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016;21(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26898240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26247435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2014 Nov 21;346(6212):996-1000</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25414313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Jul 17;12 (7):e0181093</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28715468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 Dec 15;214(12 ):1947-1951</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27923954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2011 Oct;30(10):833-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21857263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10570188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016 Sep 22;21(38):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27684603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 Apr 15;213(8):1229-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26597255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 Nov 11;354(6313):722-726</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27846599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2011 Feb 03;342:c7297</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21292718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2011 Mar;18(3):469-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21209157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2016 Aug;16(8):942-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27061888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014 Feb 06;19(5):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24524234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2014 Mar 14;6(3):1294-316</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24638204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(6):e38929</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22745690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2017 Aug 10;377(6):534-543</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28792867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):109-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24973459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med. 2013 Jun 25;11:153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23800265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Sep 1;212(5):726-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25784728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20798667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2014 Oct;8:85-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25108824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1985 May;143(1):166-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4060580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2014 Jun 6;63(22):483-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24898165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 4;33(24):2813-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25936723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25331901</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Aug;55(3):332-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22539661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2017 Jul;16(7):1-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28562111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2017 Jun 15;215(12 ):1782-1788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28398521</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2010 Jun;16(6):1023-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20507764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2015 Jul 1;125(7):2631-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26011643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21692672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 May 21;30(24):3595-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22472792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2014 Jul 1;210(1):126-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24446529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 25;9(3):e92153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24667168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2017 Sep 15;216(6):697-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28934439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Jan 15;203(2):158-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21288814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016;21(11):30168</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27020673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 May 15;213(10 ):1546-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26743842</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1529-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25406334</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000084 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000084 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeCanadaV4
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:29029166
   |texte=   Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:29029166" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV4

This area was generated with Dilib version V0.6.35.
Data generation: Sat Aug 8 18:52:12 2020. Site generation: Sat Feb 13 16:40:04 2021

	Serveur d'exploration sur la grippe au Canada
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe au Canada

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki